199 related articles for article (PubMed ID: 33011909)
21. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
22. Evolving Paradigms of Personalized Medicine in Oncology.
Dhingra K
Natl Med J India; 2017; 30(6):305-308. PubMed ID: 30117439
[No Abstract] [Full Text] [Related]
23. Normalization Cancer Immunotherapy for Melanoma.
Vesely MD; Chen L
J Invest Dermatol; 2020 Jun; 140(6):1134-1142. PubMed ID: 32092349
[TBL] [Abstract][Full Text] [Related]
24. Outlook: Immunotherapy in Gastrointestinal Carcinoma - Innovative Strategies.
Moehler M; Göpfert K; Lenz HJ
Oncol Res Treat; 2018; 41(5):313-315. PubMed ID: 29705792
[TBL] [Abstract][Full Text] [Related]
25. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
Bair SM; Mato A; Svoboda J
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
[TBL] [Abstract][Full Text] [Related]
26. Systems-Level Immune Monitoring by Mass Cytometry.
Lakshmikanth T; Brodin P
Methods Mol Biol; 2019; 1913():33-48. PubMed ID: 30666597
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy in Gastrointestinal Carcinoma - How to Separate Hope from Hype.
Moehler M
Oncol Res Treat; 2018; 41(5):264-265. PubMed ID: 29705785
[No Abstract] [Full Text] [Related]
28. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
29. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
Park JC; Hahn NM
Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
[TBL] [Abstract][Full Text] [Related]
30. CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment
Park S; Oh JH; Park DJ; Zhang H; Noh M; Kim Y; Kim YS; Kim H; Kim YM; Ha SJ; Kwon YG
Front Immunol; 2020; 11():620166. PubMed ID: 33584714
[TBL] [Abstract][Full Text] [Related]
31. Acquired resistance to cancer immunotherapy.
Draghi A; Chamberlain CA; Furness A; Donia M
Semin Immunopathol; 2019 Jan; 41(1):31-40. PubMed ID: 29968044
[TBL] [Abstract][Full Text] [Related]
32. Targeting Metabolic Bottlenecks in Lung Cancer.
Sayin VI; LeBoeuf SE; Papagiannakopoulos T
Trends Cancer; 2019 Aug; 5(8):457-459. PubMed ID: 31421901
[TBL] [Abstract][Full Text] [Related]
33. Rationale for New Checkpoint Inhibitor Combinations in Melanoma Therapy.
Mandalà M; Tondini C; Merelli B; Massi D
Am J Clin Dermatol; 2017 Oct; 18(5):597-611. PubMed ID: 28432648
[TBL] [Abstract][Full Text] [Related]
34. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
Jiang Y; Zhan H
Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
[TBL] [Abstract][Full Text] [Related]
35. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
36. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
[TBL] [Abstract][Full Text] [Related]
37. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Kashyap AS; Schmittnaegel M; Rigamonti N; Pais-Ferreira D; Mueller P; Buchi M; Ooi CH; Kreuzaler M; Hirschmann P; Guichard A; Rieder N; Bill R; Herting F; Kienast Y; Dirnhofer S; Klein C; Hoves S; Ries CH; Corse E; De Palma M; Zippelius A
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):541-551. PubMed ID: 31889004
[TBL] [Abstract][Full Text] [Related]
38. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
39. Women's cancer: Advancing molecular and immunotherapy.
Dorigo O
Curr Probl Cancer; 2017; 41(1):7. PubMed ID: 28366203
[No Abstract] [Full Text] [Related]
40. Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
Wang W; Zou W; Liu JR
Gynecol Oncol; 2018 Oct; 151(1):1-3. PubMed ID: 30243508
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
